Solara Active Pharma Sciences Ltd.
NSE: SOLARA · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
2,272cr
ROE
-0.1%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Solara Active Pharma Sciences Ltd. | 16.0% | 19.7% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Solara Active Pharma Sciences Ltd..
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Solara Active Pharma Sciences Ltd..
Shareholding
change across 4 filings| Category | Jun 26 | May 26 | Mar 26 | Dec 25 | Change |
|---|---|---|---|---|---|
| Promoters | 41.9 | 42.0 | 42.0 | 42.0 | −0.1 |
| Foreign institutions | 11.5 | 11.3 | 11.6 | 12.0 | −0.5 |
| Domestic institutions | 3.7 | 3.8 | 3.8 | 3.6 | +0.1 |
| Retail & others | 42.8 | 42.9 | 42.7 | 42.4 | +0.4 |
As filed with the exchange for the periods ending Dec 25 to Jun 26.
Filings
latest 25 of 278- Monitoring Agency Report16 Oct 2026
- Analysts/Institutional Investor Meet/Con. Call Updates16 Oct 2026
- Statement of deviation(s) or variation(s) under Reg. 3216 Oct 2026
- ESOP/ESOS/ESPS16 Oct 2026
- Press Release16 Oct 2026
- ESOP/ESOS/ESPS16 Oct 2026
- Outcome of Board Meeting16 Oct 2026
- Analysts/Institutional Investor Meet/Con. Call Updates13 Oct 2026
- Updates9 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20189 Oct 2026
- Trading Window25 Sept 2026
- Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer''s report of the Ninth Annual General Meeting22 Sept 2026
- Shareholders meeting22 Sept 2026
- Shareholders meeting18 Sept 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the Proceedings of Ninth Annual General Meeting held on September 18, 2026.18 Sept 2026
- Solara Active Pharma Sciences Limited has informed the exchange about intimation in connection with the receipt of Rectification Order28 Aug 2026
- Updates28 Aug 2026
- Copy of Newspaper Publication26 Aug 2026
- Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual report26 Aug 2026
- General Updates25 Aug 2026
- Business Responsibility and Sustainability Reporting for the financial year 2025-26.25 Aug 2026
- Annual Report for the financial year ended March 31, 202625 Aug 2026
- Shareholders meeting25 Aug 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) of the Company scheduled to be held on Friday, September 18, 202625 Aug 2026
- Copy of Newspaper Publication24 Aug 2026
The 25 most recent of 278 filings we hold for SOLARA, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.